Clinical trial coverage on Peptide News Digest pulls in Phase 1 through Phase 3 readouts across the peptide universe — GLP-1 obesity and cardiometabolic trials (SELECT, SURMOUNT-4, ACHIEVE-3, REDEFINE-1, SYNCHRONIZE-1), peptide vaccine work (AMPLIFY-201, MEL39), peptide-drug conjugate trials, and antimicrobial peptide programs.
Most of the noise sits with Lilly and Novo, but the interesting reads are usually elsewhere: Bicycle Therapeutics on solid tumors, Lirum on Ewing sarcoma, Cerapedics on lumbar fusion, Pelage on hair loss. Real-world evidence and registry data also land here when they reframe what the randomized trials showed.
Each entry names the sponsor, the phase, and the endpoint. Browse the latest below, or jump to the readouts by drug at #semaglutide, #tirzepatide, or #orforglipron.
At Saturday's Phase 3 retatrutide symposium, Lilly presented the full TRIUMPH-1 dataset in 2,339 adults with obesity or overweight without diabetes. Mean weight loss reached 28.3% (70.3 lbs) at 12 mg over 80 weeks, with 45.3% of 12 mg patients reaching at least 30% loss; in a BMI ≥35 extension, the 12 mg arm hit 30.3% (85.0 lbs) at 104 weeks. Cardiometabolic side effects included up to 41.0% triglyceride drop, 24.2% non-HDL drop, 12.3 mmHg systolic blood pressure drop, and 24.1 cm waist reduction. The 4 mg dose still produced 19.0% weight loss with discontinuation below placebo.
The first Phase 3 retatrutide diabetes trial, TRANSCEND-T2D-1, was simultaneously published in The Lancet and presented at the June 6 symposium. In adults with type 2 diabetes inadequately controlled on lifestyle alone, retatrutide produced A1C reductions of up to 2.0 percentage points and weight loss of up to 16.8% (36.6 lbs) at 40 weeks, with up to 46% achieving a normal A1C — a threshold rare in diabetes treatment trials. Systolic blood pressure and lipid markers improved across doses.
STAT reported June 6 that new safety data presented at ADA showed seven of 403 retatrutide-treated patients experienced arrhythmias and three had major cardiovascular events, compared with none in the placebo group. The signal had been a watch item ahead of ADA because retatrutide adds glucagon-receptor activity to GLP-1 and GIP, raising heart-rate and energy-expenditure mechanisms that have not appeared in the same way for semaglutide or tirzepatide. Lilly's larger TRIUMPH-OUTCOMES cardiovascular trial reads out in 2027.
ADA 2026 brought full TRIUMPH-4 results in adults with obesity and knee osteoarthritis. At the 12 mg dose, mean weight loss reached 28.7% at 68 weeks, and WOMAC pain scores dropped by an average of 4.5 points, a 75.8% reduction. The combination of substantial weight loss with a directly measured pain-and-function benefit positions retatrutide as the first obesity drug to land both endpoints in a single Phase 3.
Nature Medicine published Structure's Phase 2b ACCESS trial of aleniglipron, the once-daily oral small-molecule GLP-1, on June 5, with lead author Julio Rosenstock presenting the full data in a 12:45 p.m. CT oral session at ADA 2026 the same afternoon. The 44-week ACCESS II readout reached up to 16.3% placebo-adjusted weight loss, the strongest oral GLP-1 number outside Lilly's, and Structure plans to start Phase 3 in Q3 2026 with a 2.5 mg starting dose after end-of-Phase-2 FDA alignment.
At ADA 2026, Novo Nordisk reported full Phase 3 REIMAGINE 2 data for CagriSema (cagrilintide plus semaglutide fixed-dose combination) in 2,728 adults with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor. Over 68 weeks, CagriSema 2.4 mg/2.4 mg produced superior HbA1c reduction of 1.91 percentage points and 14.2% mean weight loss, both better than the semaglutide 2.4 mg, cagrilintide 2.4 mg, and placebo comparator arms. The readout is the first head-to-head Phase 3 win for the dual amylin/GLP-1 combination over its individual components.
Boehringer Ingelheim and Zealand Pharma presented the full Phase 3 SYNCHRONIZE-1 readout for survodutide, the glucagon/GLP-1 dual agonist, at ADA 2026. In adults with obesity or overweight without type 2 diabetes, survodutide produced up to 16.6% mean weight loss at 76 weeks versus 3.2% placebo (p<0.0001), with up to 85.1% achieving at least 5% loss. Analyst attention now turns to body composition and liver-fat substudies, with reductions driven largely by fat-tissue loss rather than lean mass.
Kailera Therapeutics and Hengrui Pharma reported positive topline Phase 3 data from a Chinese T2D trial of HRS-7535, an oral small-molecule GLP-1 receptor agonist licensed to Kailera. Most adverse events were mild-to-moderate GI, with no Grade 3 hypoglycemic events and no liver-safety signal. Hengrui plans to submit a Chinese NDA for HRS-7535 in T2D and will share detailed efficacy data at an upcoming scientific conference. The readout extends the China-led oral-GLP-1 pipeline alongside ribupatide and aleniglipron.
MetaVia's three June 7 posters at ADA cover the higher-dose Part 3 cohort of its once-weekly dual GLP-1/glucagon agonist DA-1726, which previously cleared a 32 mg dose with strong weight, glucose, and waist effects in the multiple-ascending-dose study, and two combinations of its GPR119 agonist vanoglipel: with resmetirom for synergistic hepatoprotective effects in MASH, and with metformin for joint glycemic and weight benefit. The company is small-cap but its readouts add depth to both the dual-agonist and GPR119 threads.
Lexicon Pharmaceuticals will present on Sunday, June 7 at ADA 2026: a pooled inTandem subgroup analysis of sotagliflozin, a dual SGLT-1/SGLT-2 inhibitor, in adults with type 1 diabetes (M. Belinda Hardin), and a Phase 1 study of the non-opioid pain candidate pilavapadin in patients with diabetic peripheral neuropathic pain across renal function levels (Rodica Pop-Busui). Lexicon's slate is the meeting's reminder that the diabetes pharmacology field extends beyond incretins.
Cybrexa Therapeutics' CBX-12, a 26-amino-acid pH-targeted peptide-drug conjugate that delivers a topoisomerase-1 inhibitor selectively to the acidic tumor microenvironment, completed Phase 1 in September 2024 and has moved into Phase 2 for platinum-resistant ovarian cancer. The peptide-drug conjugate field continues to broaden beyond the bicyclic-peptide and FAP-activated approaches already covered at ASCO, with smaller direct-acting peptide carriers gaining traction.
Roche will present detailed Phase 2 ZUPREME-1 data for the amylin analog petrelintide as an ADA 2026 late-breaker, with a June 8 investor event. In 493 adults with overweight or obesity (mean BMI 37), once-weekly petrelintide produced up to 10.7% mean weight loss at week 42 versus 1.7% on placebo, with treatment discontinuation of 4.8% versus 4.9% on placebo and no vomiting or GI-related discontinuations at the maximally effective dose. That tolerability is the amylin class's central pitch against the incretins.
Full Phase 3 SYNCHRONIZE-1 results for the glucagon/GLP-1 dual agonist survodutide are set for ADA 2026, detailing the obesity readout first toplined in April. In adults with obesity or overweight without type 2 diabetes, survodutide produced up to 16.6% mean weight loss at 76 weeks versus 3.2% on placebo, with up to 85.1% of treated patients losing at least 5% of body weight. The full dataset puts survodutide's glucagon component, which adds energy expenditure and liver-fat effects, in front of the field that gathers in New Orleans.
Eccogene and AstraZeneca will present multiple datasets for the oral small-molecule GLP-1 receptor agonist elecoglipron (AZD5004/ECC5004) at ADA 2026 on June 7-8, including a late-breaking Phase 1b study conducted in China, plus the Phase 2b VISTA trial in obesity (which met its primary endpoints) and the SOLSTICE Phase 2b trial in type 2 diabetes. The slate deepens the oral-GLP-1 contest forming below Lilly's orforglipron.
Structure Therapeutics will present five obesity and diabetes studies at ADA 2026, anchored by its once-daily oral small-molecule GLP-1 aleniglipron, which posted up to 16.3% placebo-adjusted weight loss at 44 weeks in the Phase 2 ACCESS II trial, among the highest reported for an oral GLP-1. The company has FDA end-of-Phase-2 alignment and plans to start a Phase 3 obesity trial in Q3 2026, with amylin and combination data also on the slate.
At ASCO 2026, Sapience Therapeutics presented updated Phase 2 data for lucicebtide (ST101), a first-in-class peptide antagonist of the transcription factor C/EBPβ, now studied in 125 patients. In newly diagnosed glioblastoma plus standard of care, projected median PFS reached 28.4 months and median OS was not yet reached, with 6 of 9 patients alive beyond 22.3 months. Spatial transcriptomics confirmed on-target activity through negative enrichment of the C/EBPβ regulon and suppression of mesenchymal transformation, with no dose-limiting toxicities or related serious adverse events.
In the June 1 rapid oral session (Abstract 4516, Yohann Loriot), the dose-optimization stage of the randomized Phase 2 Duravelo-2 trial showed the optimal dose of the bicyclic peptide-drug conjugate zelenectide pevedotin (BT8009) plus pembrolizumab produced response rates comparable to published standard-of-care data in previously untreated locally advanced or metastatic urothelial carcinoma, with roughly four-fold lower skin reactions and about half the peripheral neuropathy. The separate Duravelo-1 Phase 1 trial showed median progression-free survival comparable to standard of care in cisplatin-ineligible patients.
Mayo's randomized Phase 2 trial across 11 sites tested low-dose (825 μg) against high-dose (2.5 mg) TPIV200, a multi-epitope folate-receptor-alpha peptide vaccine adjuvanted with GM-CSF, with or without cyclophosphamide pretreatment in early-stage triple-negative breast cancer. The low dose matched the full dose on immunogenicity, cyclophosphamide pretreatment had no impact, and vaccination induced persistent polyepitope immunity. Kathryn Ruddy, Keith Knutson, and Saranya Chumsri presented the data June 1.